Improving patient-physician dialog: Commentary on the results of the MS Choices survey

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 143-152

  Lugaresi, Alessandra ^a   Ziemssen, Tjalf ^b   Oreja Guevara, Celia ^c   Thomas, Delyth ^d   Verdun, Elisabetta ^e  

^a UNIVERSITY OF CHIETI   (Italy)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d WYE VALLEY NHS TRUST   (United Kingdom)

^e MERCK SERONO S A   (Switzerland)

Author keywords

Multiple sclerosis; Patient physician dialog; Psychological profiling; Treatment adherence; Treatment initiation

Indexed keywords

NATALIZUMAB;

CLINICAL PRACTICE; CULTURAL FACTOR; DOCTOR PATIENT RELATION; HUMAN; MEDICAL DECISION MAKING; MOTIVATION; MULTIPLE SCLEROSIS; NOTE; NURSE ATTITUDE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERCEPTION; PHYSICIAN ATTITUDE; PROTOCOL COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRE; THERAPY DELAY; TREATMENT FAILURE; TREATMENT WITHDRAWAL;

EID: 84878878448     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S27932     Document Type: Note

References (27)

1. World Health Organization. Adherence to long-term therapies: evidence for action. August 11, 2003. Available from: http://www.who.int/chp/ knowledge/publications/adherence_report/en/index.html. Accessed December 1, 2009.
2. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4): 568-576.
3. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence. 2011;5: 73-84.
4. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61(4):551-554.
5. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17(6):565-576.
6. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-309.
7. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59(3-4):131-135.
8. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006;38(3): 167-171.
9. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1): 51-61.
10. Al-Sabbagh A, Bennet R, Kozma C, Dickson M, Meletiche D. Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol. 2008; 255(Suppl 2):321.
11. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
12. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv. 2009;6(9):995-1002.
13. Pozzilli C, Schweikert B, Ecari U, Oentrich W. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis-results of the BetaPlus observational cohort study. J Neurol Sci. 2011;307(1-2): 120-126.
14. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(5):585-591.
15. Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Rev Neurol (Paris). 2006;162(6-7): 735-740. French.
16. Riñón A, Buch M, Holley D, et al. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing MS. Patient Pref Adherence. 2011;5:629-643.
17. Devonshire V, Lapierre Y, MacDonell R, et al. The Global Adherence Project-a multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. Mult Scler. 2006;12 (Suppl 1):S229-S243.
18. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69-77.
19. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler. 2010;16(12):1507-1512.
20. Kern S, Schrempf W, Schneider H, Schultheiss T, Reichmann H, Ziemssen T. Neurological disability, psychological distress, and healthrelated quality of life in MS patients within the first three years after diagnosis. Mult Scler. 2009;15(6):752-758.
21. Durelli L, Bongioanni MR, Ferrero B, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology. 1996;47(1):123-129.
22. Borreani C, Giordano A, Falautano M, et al. Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial. Health Expect. 2011. [Epub ahead of print.] doi: 10.1111/j.1369-7625.2011.00736.x.
23. Solari A, Martinelli V, Trojano M, et al. An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Mult Scler. 2010;16(11):1393-1405.
24. Schultheiss T, Kempcke R, Kratzsch F, et al. [Multiple sclerosis management system 3D: moving from documentation towards management of patients]. Nervenarzt. 2011. [Epub ahead of print.] doi: 10.1007/s00115-011-3376-6. Article in German.
25. Kern S, Reichmann H, Ziemssen T. Adherence to neurologic treatment. Lessons from multiple sclerosis. Nervenarzt. 2008;79(8):877-886. German.
26. Heesen C, Kasper J, Segal J, Kopke S, Muhlhauser I. Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. Mult Scler. 2004;10(6):643-650.
27. Giordano A, Mattarozzi K, Pucci E, et al. Participation in medical decision-making: attitudes of Italians with multiple sclerosis. J Neurol Sci. 2008;275(1-2):86-91.